AI Article Synopsis

  • The article discusses three main pathologic types of plasmacytoid dendritic cells (pDCs) found in relation to myeloid neoplasms, which are blood cancers.
  • The types include: 1) pDC expansion typically linked to chronic myelomonocytic leukaemia (CMML), 2) pDC differentiation seen in acute myeloid leukaemia (AML) with various maturation stages, and 3) neoplasms associated with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
  • The authors also provide a diagnostic algorithm and aim to standardize terminology for the different states of pDCs in these conditions.

Article Abstract

In this article, we describe three broad pathologic presentations of plasmacytoid dendritic cells (pDCs) that may be encountered in clinical practice, in which an association between pDCs and myeloid neoplasms is identified: (1) myeloid neoplasms with mature pDC expansion, most commonly seen in chronic myelomonocytic leukaemia (CMML); (2) myeloid neoplasms with pDC differentiation, in which pDCs show a spectrum of maturation from early immature pDCs to mature forms, most commonly seen in acute myeloid leukaemia (AML); (3) myeloid neoplasms associated with blastic plasmacytoid dendritic cell neoplasm (BPDCN), either stemming from the same precursor or representing an independent clonal process. Additionally, we also discuss AML with pDC-like phenotype, in which myeloblasts show immunophenotypic features that may mimic those seen in pDCs. Using these presentations, we provide a diagnostic algorithm for appropriate pathologic classification, while attempting to clarify and homogenize nomenclatures pertaining to different biologic states of pDCs.

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.18632DOI Listing

Publication Analysis

Top Keywords

myeloid neoplasms
20
plasmacytoid dendritic
12
dendritic cells
8
pathologic presentations
8
myeloid
6
pdcs
6
neoplasms
5
cells setting
4
setting myeloid
4
neoplasms diagnostic
4

Similar Publications

An adolescent girl with acute myeloid leukaemia underwent chemotherapy followed by haematopoietic stem cell transplantation (HSCT). Post-HSCT, she developed oral chronic graft-versus-host disease (cGvHD), which was successfully treated. Twenty months later, she was referred to the gynaecology department for evaluation of secondary amenorrhoea.

View Article and Find Full Text PDF

How I Treat Higher-Risk MDS.

Blood

January 2025

H. Lee Moffitt Cancer Center, Tampa, Florida, United States.

Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphologic dysplasia, a defective hematopoiesis, and recurrent genetic abnormalities. The original and revised International Prognostic Scoring Systems (IPSS) have been used to risk-stratify patients with MDS to guide treatment strategies. In higher-risk MDS, the therapeutic approach is geared toward delaying leukemic transformation and prolonging survival.

View Article and Find Full Text PDF

Background: AML-M4Eo is a type of AML characterized by malignant proliferation of granulocyte and monocyte precursor cells accompanied by eosinophilia. Patients present as anemia, infection, bleeding, and tissue and organ infiltration. MICM classification makes the classification of AML more accurate and lays a foundation for the correct treatment and prognosis of AML.

View Article and Find Full Text PDF

Background: Acute myeloid leukemia (AML) is a hematologic malignancy. It is the most common form of acute leukemia among adults. Recent treatment advances have drastically improved outcomes for these diseases, but the overall survival (OS) is still exceptionally low due to the infiltration of leukemic cells in the central nervous system (CNS).

View Article and Find Full Text PDF

Background: Platelets are correlated with myeloid leukemia (ML), but to date, there have been no studies confirming the causal relationship between them.

Methods: Platelet count (PLT), mean platelet volume (MPV), plateletcrit (PCT), and platelet distribution width (PDW) data were obtained from the GWAS catalog database as exposure factors. Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) data were obtained from the FinnGen database as outcome indicators.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!